Ten departments including the Ministry of Industry and Information Technology and the National Development and Reform Commission jointly released the “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry” today. According to the “Plan”, the operating income of large-scale pharmaceutical industry enterprises will exceed 3.5 trillion yuan in 2030. The “Plan” focuses on predictive indicators for the development of the pharmaceutical industry during the “15th Five-Year Plan” period, focusing on the large-scale efficiency of the industry, innovative development, enterprise cultivation, and cluster development. These include: the scale efficiency of the industry has been steadily increasing; the scale growth rate of the innovative pharmaceutical industry has reached more than 20% per year; the number of varieties with global annual sales exceeding 1 billion US dollars has reached more than 5; the number of pharmaceutical industry enterprises with annual revenue exceeding 10 billion yuan has reached 50, and the number of 100 billion pharmaceutical industrial parks has reached 20. In terms of innovation and development, the goals proposed in the “Plan” are: the average R&D investment intensity of listed companies in the pharmaceutical industry reaches an average of 10% or more per year, and the first innovative drugs account for more than 25% of the world.

Ten departments including the Ministry of Industry and Information Technology and the National Development and Reform Commission jointly released the “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry” today. According to the “Plan”, the operating income of large-scale pharmaceutical industry enterprises will exceed 3.5 trillion yuan in 2030. The “Plan” focuses on predictive indicators for the development of the pharmaceutical industry during the “15th Five-Year Plan” period, focusing on the large-scale efficiency of the industry, innovative development, enterprise cultivation, and cluster development. These include: the scale efficiency of the industry has been steadily increasing; the scale growth rate of the innovative pharmaceutical industry has reached more than 20% per year; the number of varieties with global annual sales exceeding 1 billion US dollars has reached more than 5; the number of pharmaceutical industry enterprises with annual revenue exceeding 10 billion yuan has reached 50, and the number of 100 billion pharmaceutical industrial parks has reached 20. In terms of innovation and development, the goals proposed in the “Plan” are: the average R&D investment intensity of listed companies in the pharmaceutical industry reaches an average of 10% or more per year, and the first innovative drugs account for more than 25% of the world.